短腸症候群市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、流通チャネル別、地域別、競合別、2020-2030年

世界の短腸症候群（SBS）市場は、2024年に8億5,402万米ドルと評価され、予測期間中の複合年間成長率（CAGR）6.73％を反映して、2030年には12億6,538万米ドルに達すると予測されています。

SBSは、消化器系、特に小腸に影響を及ぼすまれで衰弱性の疾患です。SBS患者は栄養と水分の吸収能力が低下し、栄養失調、脱水、その他の様々な健康合併症を引き起こす可能性があります。近年、世界のSBS市場は大きな進歩を遂げ、患者にもヘルスケアプロバイダーにも新たな希望をもたらしています。

SBSは一般的に、小腸のかなりの部分が外科的に切除されたり、損傷されたりすることで発症します。多くの場合、先天性欠損、外傷、クローン病のような疾患などの要因が原因です。クローン病の表現型と併存疾患、手術リスク、薬物療法、非薬物療法との関連性」と題された最近の研究によると、クローン病の表現型と併存疾患、手術リスク、薬物療法、非薬物療法との関連性は、クローン病の表現型と併存疾患、手術リスク、薬物療法、非薬物療法との関連性である：The MAGIC in IMAGINE Study "と題された最近の研究では、クローン病（CD）と新たに診断された成人673人を対象とした日本での研究で、63％が炎症性表現型を示し、60％が回腸病変を有し、49％が肛門周囲病変を有し、肛門周囲病変（膿瘍や瘻孔など）の有病率が際立って高いことが明らかになりました。アジアにおける調査では、炎症性疾患の有病率はさらに高く、66％から81％であったと報告されています。

主な市場促進要因

主な市場課題

主な市場動向

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の短腸症候群市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別（GLP-2、グルタミン、成長ホルモン）
  • 流通チャネル別（病院薬局、オンライン販売、小売薬局）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の短腸症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の短腸症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の短腸症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の短腸症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの短腸症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（該当する場合）
• 製品の発売（該当する場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Wellspect Healthcare（Dentsply Sirona Company）
• Emmaus Life Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• OPKO Health, Inc.
• OxThera AB
• Pfizer Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

The global Short Bowel Syndrome (SBS) market was valued at USD 854.02 million in 2024 and is projected to reach USD 1,265.38 million by 2030, reflecting a compound annual growth rate (CAGR) of 6.73% over the forecast period. SBS is a rare and debilitating condition that impacts the digestive system, particularly the small intestine. Individuals with SBS experience a reduced ability to absorb nutrients and fluids, which can result in malnutrition, dehydration, and various other health complications. In recent years, the global SBS market has experienced significant advancements, bringing new hope to patients and healthcare providers alike.

SBS typically arises from the surgical removal or damage of a substantial portion of the small intestine, often caused by factors such as congenital defects, trauma, or diseases like Crohn's disease. According to a recent study titled "Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications, and Nonmedication Approaches: The MAGIC in IMAGINE Study", a study in Japan on 673 newly diagnosed adults with Crohn's disease (CD) found that 63% exhibited an inflammatory phenotype, 60% had ileocolonic disease, and 49% had perianal lesions, with the prevalence of perianal disease (such as abscesses or fistulas) being notably high. Studies across Asia have reported even higher rates of inflammatory disease, ranging from 66% to 81%.

Key Market Drivers

The increasing incidence of Short Bowel Syndrome is driving market growth. As the number of SBS cases rises, the demand for treatments and therapies has surged, contributing to the market's expansion. Pharmaceutical companies are heavily investing in research and development to create medications that enhance nutrient absorption for SBS patients and help them manage their condition. These innovations are a significant factor in the market's growth. Parenteral nutrition, which delivers essential nutrients intravenously, has become a critical treatment for SBS patients, leading to a rise in demand for these solutions and associated equipment. Additionally, enteral nutrition, involving specialized formulas designed for SBS patients, plays a crucial role in managing the condition. Advances in minimally invasive surgical techniques and small bowel transplantation have also improved patient outcomes, further driving market expansion. Increased awareness of SBS and the advocacy efforts of patient groups have led to additional research funding and resources, fostering further market growth. Although SBS is rare, with an estimated prevalence of 1-2 cases per 100,000 individuals annually, its growing recognition is accelerating the development of treatment options.

Key Market Challenges

A major challenge for the SBS market is the limited patient pool. As SBS is classified as a rare disease, the number of diagnosed cases globally is relatively small, limiting the overall market size and the number of patients requiring specialized treatments. This restricted patient base can deter pharmaceutical companies from investing heavily in the development of new therapies, as the potential return on investment is lower. Consequently, promising treatments may not receive the attention they deserve, hindering progress in the field. Additionally, the fragmented nature of the patient pool complicates large-scale clinical trials and the collection of sufficient data to prove the efficacy of new therapies, creating a cycle of underinvestment and delayed progress.

Key Market Trends

Technological advancements have significantly influenced the growth of the global SBS market. Recent medical innovations are improving the management and treatment of SBS, offering hope for affected individuals. Pharmaceutical companies are actively developing new drugs and therapies to address the causes and symptoms of SBS. A notable advancement is Zealand Pharma A/S's phase 3 study of Glepaglutide, a long-acting GLP-2 analog that could potentially outperform existing treatments, such as Teduglutide, due to its benefits, including weekly administration and extended action. Furthermore, the development of specialized nutritional supplements tailored for SBS patients has greatly improved their quality of life.

Key Market Players

• Wellspect Healthcare (Dentsply Sirona Company)
• Emmaus Life Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• OPKO Health, Inc.
• OxThera AB
• Pfizer Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Report Scope

This report provides a detailed analysis of the global Short Bowel Syndrome market, segmented into the following categories, in addition to examining industry trends:

By Drug Class:

• GLP-2
• Glutamine
• Growth Hormone

By Distribution Channel:

• Hospital Pharmacies
• Online Sales
• Retail Pharmacies

By Region:

• North America:
• United States
• Canada
• Mexico
• Europe:
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific:
• China
• India
• Japan
• Australia
• South Korea
• South America:
• Brazil
• Argentina
• Colombia
• Middle East & Africa:
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

This report includes detailed profiles of the leading companies operating in the SBS market.

Available Customizations: TechSci Research offers tailored customizations of the Global Short Bowel Syndrome market report to meet specific business requirements. The following customization options are available:

• Company Information: In-depth analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short Bowel Syndrome Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (GLP-2, Glutamine, and Growth Hormone)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Short Bowel Syndrome Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Short Bowel Syndrome Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Short Bowel Syndrome Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Short Bowel Syndrome Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Short Bowel Syndrome Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Short Bowel Syndrome Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. United Kingdom Short Bowel Syndrome Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Italy Short Bowel Syndrome Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. France Short Bowel Syndrome Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Short Bowel Syndrome Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Short Bowel Syndrome Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Short Bowel Syndrome Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Short Bowel Syndrome Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Short Bowel Syndrome Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Short Bowel Syndrome Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Short Bowel Syndrome Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. South America Short Bowel Syndrome Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Short Bowel Syndrome Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Short Bowel Syndrome Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Short Bowel Syndrome Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Short Bowel Syndrome Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Short Bowel Syndrome Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Short Bowel Syndrome Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Short Bowel Syndrome Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Wellspect Healthcare (Dentsply Sirona Company)
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Emmaus Life Sciences, Inc.
• 14.3. Merck & Co., Inc.
• 14.4. Novartis AG
• 14.5. OPKO Health, Inc.
• 14.6. OxThera AB
• 14.7. Pfizer Inc.
• 14.8. Swedish Orphan Biovitrum AB
• 14.9. Takeda Pharmaceutical Company Limited
• 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer